ABOUT EVENT
Welcome to the 14th World Clinical Biomarkers & CDx Summit!
The 14th World Clinical Biomarkers & Companion Diagnostics Summit is your premier four-day forum dedicated to advancing biomarker research and companion diagnostics. Gathering leading biopharma, academia, service and solution providers, this meeting fosters meaningful conversations around the industry’s latest developments, regulatory changes, and innovative strategies.
Three days of comprehensive data-driven sessions, panel discussions, and networking opportunities will explore key topics such as:
- The impact of global regulatory frameworks
- Advancements in precision oncology
- The integration of AI and digital pathology
Gain insights into patient-centric approaches and the importance of equitable access to precision medicine, knowledge-share, and collaborate to drive innovation and improve patient outcomes in clinical biomarkers and companion diagnostics.
Ensure you’re positioned at the forefront of this rapid-evolving field by joining the pre-conference thought leadership workshops hosted by our partners Foundation Medicine, Roche, Quest Diagnostics, and Guardant.
What's New?
500+
Attendees
50+
Biopharma Speakers
30+
New Companies
13+
Hours of In-Person Networking
1
Scientific Poster Session
Who Attends this Meeting?
A Snapshot of Hot Sessions:
Day 1:
Unleashing the Power of Digital Pathology & AI to Accelerate Drug Development Across All Therapeutic Areas
Michael Montalto, Vice President – Precision Medicine, Amgen
Bringing the First Precision Medicine to Treat CNS Diseases using Innovative Biomarker Discovery Platforms
Wen Luo, Chief Executive Officer/Chief Scientific Officer, Denovo Biopharma LLC
Advancing Precision Medicine in Early Bladder Cancer with Urine Assay Technology
David Weingeist, Scientific Director, Oncology Precision Medicine & Diagnostics, Johnson & Johnson
Day 2:
Integrating the Patient Perspective in Clinical Biomarker Development & Companion Diagnostics for Enhanced Patient
Ann Fish-Steagall, Senior Vice President - Patient Services, LUNGevity Foundation
Leveraging MRD to Develop Personalized Treatment Options
Duane Hassane, Senior Director - Head of Translational Omics, Haematology R&D, AstraZeneca
Developing & Executing Proof of Mechanism Strategies to Increase the Speed and Quality of Decision Making
Amanda Wang, Vice President, Head of Translational Science Leader Hub, Bayer Science
Day 3:
Leveraging Effective Communication Strategies to Enhance Stakeholder Engagement in Clinical Biomarker Development
Sharon Moulis, Senior Director - Precision Medicine and Companion Diagnostics, Pfizer
Navigating the Complexity of Integrating Companion Diagnostic Development & Large-Scale Patient Screening into Late Phase Oncology Drug Development
Diarmuid Moran, Head of Precision Medicine and Diagnostics, Astellas Innovation Management LLC
Catalyzing Global Breakthroughs with Strategic Partnerships & Patient-Centric Precision Medicine for a Healthier Future
Flora Berisha, Global Head of Diagnostics Partnering & Development, Precision Medicine, Johnson & Johnson Services, Inc
